Abstract
Organ transplantation and the subsequent life-long immunosuppression increases the risk of developing a maliganancy after transplantation. This is well in accordance with the assumption that an impaired immune system permits carcinogenic factors to act uncontrolled. Several studies have demonstrated an overall cancer incidence of 6%, ranging from 4–18%, which is 3–5 times higher than that of the general population [1, 2]
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Penn I. Tumours after renal and cardiac transplantation. Hematology/Oncology Clinics of North America, 7: 431–445,1993.
Penn I. Malignant neoplasia in the immunosup-pressed patient. In Cooper DKC, Novitsky D eds. The transplantation and replacement of thoracic organs. The presents status of biological and mechanical replacement of the heart and lungs. Dordrecht, Kluwer Academic Publishers, 1990; p 183.
Penn I. The effect of immunosuppression on preexisting cancers. Transplantation 55(4): 742–747, 1993.
Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg, 25: 367–472,1988.
Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M, Hardsty RL. Dummer JS. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 10: 877–886,1991.
Penn I. De novo cancers in organ allograft recipients. Curr Opinion in Organ Transpl, 3: 188–196, 1998.
Nalesnik MA. Clinicopathologic features of post-transplant lymphoproliferative disorders. Ann Transplant 2: 33–40,1997.
Nalesnik MA, Locker, Jaffe R, Reyes J, Cooper M, Fung J, Starzl TE. Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transpl 6: 249–252,1992.
Penn I. Posttransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 2(1): 52–59,1996.
Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med (1A): 44,195.
Penn I. Malignancy. Surg Clin N Am, 74(5): 1247–1257,1994.
Penn I. Posttransplant malignancies in pediatric organ transplant recipients. Transplant Proc 26 (sn5): 2763–2765,1994.
Hanto DW. Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annual Rev Med 46: 381–394,1995.
Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45: 719–727,1988.
Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Haberman TM, Daly RC, McGregor CG. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung and other solid organ transplantation. J Heart Lung Transplant 14: 214–221,1995.
Hiesse C, Kriaa F, Rieu P, Larue JR, Benoit G, Bellamy J, Blanchet P, Charpentier B. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporinetreated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc 27(1): 972–974, 1995.
Morrison VA, Dunn DL, Manivel JC, Gajl Peczalska KJ, Peterson BA. Clinical characteristics of posttransplant lymphoproliferative disorders. Am J Med 97(1): 14–24,1994.
Wu TT, Swerdlow SH, Locker J, Bahier D, Randhawa PS, Yunis E, Dickman PS, Nalesnik MA. Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients. Hum Pathol 27: 157–164,1996
Penn I. Risks of recurrence of posttransplant lymphoproliferative disease, Hodgkin_s disease or Kaposi_s sarcoma after retransplantation. In Touraine JL, Traeger J, Bétuel H, Dubernard JM, Revillard JP, Dupuy C eds. Retransplantation. Dordrecht, Kluwer Academic Publishers, pp 45–53, 1997.
Brunner FP, Landais P, Seiwood H. Malignancies after renal transplantation: the EDTA-ERA registry experience. Nephrol Dial Transplant 10(1): 74–80,1995.
Penn I. Recent results in cancer research. N.Y., Springer-Verlag Inc., 69: 7–13,1979.
Kirchner KA, Files JC, Didlake R, Seshadri R, Krueger RP. Chronic granulocytic leukemia after renal transplantation. Arch Intern Med, 143: 1984–1987, 1983.
Shima T, Oku N, Goto H, Inaba T, Murakami S, Itoh K, Fujita N, Shimazaki C, Misawa S, Nakagawa M. Chronic myelomonocytic leukemia and esophageal cancer developed in a renal allograft recipient. Rinsho Ketsueki (Japanese Journal of Clinical Hematology), 34(7): 842–846,1993.
Hand MF, Anderton JL. Acute myleoid leukaemia following renal transplantation and previous Wilms_ tumour. Nephr Dialysis Transpl, 7(7): 653, 1992.
Adler KR, Lempert N, Scharfman WB. Chronic granulocytic leukemia following successful renal transplantation. Cancer 41: 2206–2208,1978.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Wilczek, H.E., Brattström, C. (2001). Hematologic Malignancies Following Organ Transplantation. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J., Creutzig, U. (eds) Acute Leukemias VIII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 40. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18156-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-18156-6_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62109-3
Online ISBN: 978-3-642-18156-6
eBook Packages: Springer Book Archive